Loader

Pathways

PathWhiz ID Pathway Meta Data

PW145636

Pw145636 View Pathway
drug action

Rotigotine Drug Metabolism Action Pathway

Homo sapiens

PW145597

Pw145597 View Pathway
drug action

Roxadustat Drug Metabolism Action Pathway

Homo sapiens

PW000711

Pw000711 View Pathway
drug action

Roxatidine Acetate Action Pathway

Homo sapiens
Roxatidine acetate is an anti-ulcer agent, that works through antagonizing the histamine H2 receptor. It is used to reduce abdominal pain, heartburn, acid indigestion and acid reflux. The pathway begins in the stomach, where roxatidine acetate inhibits the histamine H2 receptor on the surface of the parietal cell. Now in the gastric endothelial cell, potassium-transporting ATPase units are inhibited by G-Protein signalling cascade through somatostatin receptor type 4, which is activated by somatostatin. At the same time, potassium-transporting ATPase is activated by the G-protein signalling cascade, through histamine H2 receptor which is inhibited by ranitidine, gastrin/cholecystokinin type B receptor, and muscarinic acetylcholine receptor M3 which are activated by histamine, gastrin and acetylcholine, respectively. The potassium transporting ATPase also converts water and ATP to a phosphate molecule and ADP. Alongside the transporters, potassium is brought into the cell. Carbonic anhydrase 1 uses water and carbon dioxide to create hydrogen carbonate and a hydrogen ion, which are both transported out of the endothelial cell, into the gastric lumen. A chloride ion is transported into the gastric endothelial cell through a chloride anion exchanger and is transported out of the cell through a chloride intracellular channel protein 2, back into the gastric lumen.

PW124517

Pw124517 View Pathway
drug action

Roxatidine Acetate H2 Anti-Histamine Action Pathway

Homo sapiens
Roxatidine Acetate is an histamine H2 receptor antagonist used to treat stomach ulcers and Gastroesophageal Reflux Disease (GERD). After being taken orally, it is absorbed in the GI tract and travels through the blood to get to the stomach epithelium. Ranitidine binds reversibly to the histamine H2 receptor blocking histamine from binding instead. This blocks the downstream Gs cascade which produces cyclic adenosine monophosphate (cAMP) which is an activator for the potassium-hydrogen ATPase pump (H+/K+ ATPase pump). The pump is responsible for secreting hydrogen ions into the stomach lumen increasing the acidity of the stomach environment. By blocking adenylate cyclase signalling pathway from the histamine H2 receptor less hydrogen ions are secreted into the stomach lumen increasing the pH. The less acidic environment doesn't irritate the stomach as much. The H+/K+ ATPase pump can still be activated through gastrin and acetylcholine through the phospholipase C signalling pathway, but blocking the adenylate cyclase pathway helps reduce the acidity.

PW125948

Pw125948 View Pathway
drug action

Roxithromycin

Homo sapiens
Roxithromycin is an oral antibiotic drug used for the treatment of bacterial infections including respiratory tract infections, skin infections and urinary infections. It is a semi-synthetic macrolide antibiotic very similar structurally and pharmacologically to erythromycin, claithromycin and azithromycin. Roxithromycin is partially metabolized in the liver into 3 metabolites descladinose roxithromycin, N-mono and N-di-demethyl roxithromycin . Roxithromycin then penetrates the bacterial cell wall and act synergistically to inhibit protein synthesis. This compound acts on the 50S subunit of the bacterial ribosome inhibiting the translocation of the aminoacyl transfer-RNA, preventing the addition of the next amino acid to the growing polypeptide chain. As a result, protein synthesis is inhibited, preventing bacterial growth and this may even kill the bacteria. Some adverse side effects of Roxithromycin is gastrointestinal problems such as diarrhea, nausea, abdominal pain and vomiting. In some rare instances one can also experience headaches, rashes, alteration of taste and smell as well as some abnormalities with liver function.

PW000349

Pw000349 View Pathway
drug action

Roxithromycin Action Pathway

Homo sapiens
A member of the semi-synthetic macrolide class of antibiotics, roxithromycin is employed in infections of the respiratory tract, urinary, and soft tissue infections. Its macrocyclic lactone ring and deoxy sugars, defining features of macrolide antibiotics, mediates its mechanism of action as it inhibits peptide translocation by binding to the 50S subunit of the bacterial ribosome. Protein synthesis is thus inhibited by ribosomal binding. It has been demonstrated to have a longer half-life compared to other macrolide antibiotics such as erythromycin and is effective against certain Gram-negative bacteria.

PW124610

Pw124610 View Pathway
drug action

Roxithromycin Anti=Bacterial Action Pathway

Homo sapiens
Roxithromycin is an oral antibiotic drug used for the treatment of bacterial infections including acute otitis media caused by H. influenzae, M. catarrhalis, or S. pneumoniae in patients with a history of type I penicillin hypersensitivity, pharyngitis and tonsillitis caused by susceptible Streptococcus pyogenes, respiratory tract infections including acute maxillary sinusitis, acute bacterial exacerbations of chronic bronchitis, mild to moderate community-acquired pneuomia, Legionnaires' disease, and pertussis, skin or skin structure infections, helicobacter pylori infection, duodenal ulcer disease, bartonella infections, early Lyme disease, and encephalitis caused by Toxoplasma gondii (in HIV infected patients in conjunction with pyrimethamine). Roxithromycin penetrates the bacterial cell wall of usually gram negative bacteria and act synergistically to inhibit protein synthesis. These compounds act by binding to domain V of the 23S ribosomal RNA of the 50S subunit of the bacterial ribosome. This inhibits translocation of the aminoacyl transfer-RNA, preventing the addition of the next amino acid to the growing polypeptide chain. As a result, protein synthesis is inhibited, preventing bacterial growth and this may even kill the bacteria. Roxithromycin was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila.

PW144887

Pw144887 View Pathway
drug action

Roxithromycin Drug Metabolism Action Pathway

Homo sapiens

PW146362

Pw146362 View Pathway
drug action

Rubidium Drug Metabolism Action Pathway

Homo sapiens

PW146163

Pw146163 View Pathway
drug action

Rubidium Rb-82 Drug Metabolism Action Pathway

Homo sapiens